Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea
· Delayed Price · Currency is KRW 3,170.00
-45.00 (-1.40%)
Jun 27, 2025, 3:30 PM KST
Xcell Therapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | -9,828 | -9,543 | -9,281 | -8,342 | -9,038 | -10,124 | Upgrade
|
| Depreciation & Amortization | 1,688 | 1,653 | 1,598 | 1,513 | 1,019 | 681.79 | Upgrade
|
| Loss (Gain) From Sale of Assets | 130.13 | 130.13 | -21 | 0.53 | 12 | -3 | Upgrade
|
| Asset Writedown & Restructuring Costs | -130.13 | - | 154.12 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -9.43 | -2.72 | 0.87 | - | - | - | Upgrade
|
| Stock-Based Compensation | 239.66 | 228.31 | 283.67 | 540.12 | 354.46 | 74.09 | Upgrade
|
| Provision & Write-off of Bad Debts | 394.96 | 259.89 | 50 | - | - | - | Upgrade
|
| Other Operating Activities | 461.9 | 383.97 | 587.39 | 230.17 | 3,453 | 5,789 | Upgrade
|
| Change in Accounts Receivable | -266.49 | -31.37 | -301.81 | -104.98 | -133.14 | -16.93 | Upgrade
|
| Change in Inventory | 55.9 | 60.58 | -178.38 | -186.23 | 179.52 | -37.8 | Upgrade
|
| Change in Accounts Payable | -647.2 | 46.38 | 43.66 | -137.29 | -239.85 | -82.44 | Upgrade
|
| Change in Other Net Operating Assets | -559.7 | -180.91 | 280.29 | -808.69 | -211.69 | -258.36 | Upgrade
|
| Operating Cash Flow | -8,470 | -6,996 | -6,784 | -7,296 | -4,605 | -3,978 | Upgrade
|
| Capital Expenditures | -1,068 | -382.69 | -224.82 | -1,179 | -1,347 | -1,679 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 55 | - | 0.45 | 3 | Upgrade
|
| Sale (Purchase) of Intangibles | -595.86 | -437.34 | -8.83 | -145.48 | -49.14 | -17.36 | Upgrade
|
| Investment in Securities | -771.67 | -1,780 | -3.96 | -131.88 | -3.88 | 14.07 | Upgrade
|
| Other Investing Activities | 1,298 | 1,328 | 4.06 | -10 | -259.51 | 132.67 | Upgrade
|
| Investing Cash Flow | -1,137 | -1,272 | -178.55 | -1,466 | -1,659 | -1,546 | Upgrade
|
| Long-Term Debt Issued | - | 1,950 | 350 | - | 3,000 | 2,270 | Upgrade
|
| Long-Term Debt Repaid | - | -3,035 | -587.44 | -455.54 | -759.28 | -1,587 | Upgrade
|
| Net Debt Issued (Repaid) | -1,544 | -1,085 | -237.44 | -455.54 | 2,241 | 683.45 | Upgrade
|
| Issuance of Common Stock | 15,925 | 15,875 | 3,000 | 16.66 | 8,092 | 6,000 | Upgrade
|
| Other Financing Activities | -0 | -0 | - | - | - | - | Upgrade
|
| Financing Cash Flow | 14,381 | 14,790 | 2,763 | -438.88 | 14,232 | 11,384 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1,236 | 1,239 | 2.2 | 4.66 | 2.15 | - | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | - | - | 0 | Upgrade
|
| Net Cash Flow | 6,010 | 7,761 | -4,197 | -9,196 | 7,971 | 5,859 | Upgrade
|
| Free Cash Flow | -9,538 | -7,379 | -7,008 | -8,475 | -5,952 | -5,657 | Upgrade
|
| Free Cash Flow Margin | -547.39% | -381.48% | -623.58% | -830.82% | -302.69% | -1047.18% | Upgrade
|
| Free Cash Flow Per Share | -912.96 | -737.48 | -792.48 | -968.02 | -718.67 | -1578.43 | Upgrade
|
| Cash Interest Paid | 271.66 | 343.69 | 284.27 | 209.73 | 104.88 | 78.33 | Upgrade
|
| Cash Income Tax Paid | 30.01 | 23.06 | -8.31 | 11.26 | 3.73 | - | Upgrade
|
| Levered Free Cash Flow | -7,248 | -5,076 | -3,926 | -5,606 | -6,886 | -1,445 | Upgrade
|
| Unlevered Free Cash Flow | -7,246 | -5,074 | -3,924 | -5,604 | -6,774 | -927.88 | Upgrade
|
| Change in Net Working Capital | 1,211 | 155.23 | -220.51 | 933.87 | 3,073 | -2,810 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.